The Burn Center at MedStar Washington Hospital Center cared for 10 critically injured Pentagon patients and helped shape the future of burn care.

WASHINGTON, Sept. 11, 2026 /PRNewswire/ -- Twenty-five years later, three survivors of the Sept. 11, 2001, Pentagon attack returned to the Burn Center at MedStar Washington Hospital Center, where they received lifesaving care and began their long road to recovery after one of the nation's deadliest terrorist attacks.

The survivors reunited with caregivers and toured the Burn Center, including the newly renovated intensive care unit, step-down unit, and rehabilitation gym where they spent weeks and months recovering from devastating injuries. Their visit underscored the resilience of survivors, the dedication of healthcare teams who cared for them, and the lasting bonds formed through tragedy.

The three survivors spent between five weeks and three months at MedStar Washington Hospital Center after sustaining severe burn injuries in the attack.

- HON Brian Birdwell, now Assistant Secretary of War for Sustainment at the Pentagon and a retired Army lieutenant colonel, suffered severe burns over more than 60% of his body. He underwent dozens of surgeries and months of rehabilitation during his recovery. Since then, HON Birdwell has dedicated his life to public service and has become a nationally recognized advocate and speaker on resilience and leadership.

- Maj. David King worked in the Pentagon's Office of the Chief of Staff of the Army (G-8) and was the sole survivor from his office. He sustained burns to 22% of his body and endured multiple surgeries, skin grafts, and extensive physical therapy. After approximately five weeks in the hospital, he returned to military service in January 2002 and retired from the Army in 2008.

- John Yates, a security manager at the Pentagon, sustained burns to 38% of his body and was the sole survivor from his office. He spent over two months in the hospital, where he relearned many of the basic tasks of everyday life during his recovery. He returned to work in Jan. 2002 and retired in 2016.

The Burn Center at MedStar Washington Hospital Center played a critical role in the region's emergency response following the attack on the Pentagon. As the Washington region's only adult Burn Center, its physicians, nurses, therapists, and support staff rapidly mobilized to care for 10 patients suffering from severe burns, inhalation injuries, and complex trauma. Many required multiple reconstructive surgeries, specialized wound care, respiratory support, rehabilitation services, and long-term follow-up.

The national spotlight turned to the hospital on Sept. 13, 2001, when President George W. Bush and First Lady Laura Bush visited patients, families, and healthcare workers, thanking them for their courage and service during one of the most challenging moments in the nation's history.

"The lessons learned from caring for survivors of the Pentagon attack helped shape burn disaster preparedness, emergency response planning, and multidisciplinary burn care in the years that followed," said Jeffrey Shupp, MD, director of the Burn Center at MedStar Washington Hospital Center. "Since 2001, advances in critical care, wound management, infection prevention, skin grafting techniques, reconstructive surgery, pain management, rehabilitation, and aftercare have dramatically improved outcomes for patients with severe burn injuries."

Dr. Shupp was a graduate student at the University of Maryland on Sept. 11, 2001. In the years that followed, he spent hundreds of hours learning from the late Marion Jordan, MD, former director of the Burn Center, whose leadership during and after the Pentagon attack earned the Burn and Trauma teams worldwide recognition for their expertise in caring for some of the nation's most critically injured survivors.

Today, the Burn Center continues to serve as a regional, national, and international leader in burn care, providing comprehensive treatment from emergency care through rehabilitation, reconstruction, and social reintegration. The program cares for patients with some of the most complex traumatic injuries, helping them recover, regain independence, and return to their families, jobs, and communities.

The return of these three survivors stands as a testament to the lifesaving care delivered in the aftermath of Sept. 11 and the remarkable advances in burn medicine made over the past 25 years.

Download photos, B-roll and soundbites (SOT) from the survivors' visit with their care teams HERE.

Order of SOT:

- HON Brian Birdwell

- John Yates

- Maj. David King

- Ron Lassiter

- Jeffrey Shupp, MD

SOURCE MedStar Health

Share this article

In the news release, Fewer Blood Components Transfused with fibryga® Than Cryoprecipitate, Secondary Analysis of Prespecified FIBRES Subgroups Reports, issued 09-Sep-2026 by Octapharma over PR Newswire, we are advised by the company that the fifth paragraph, second sentence, should read "16% relative reduction" rather than "19% relative reduction" as originally issued inadvertently. The complete, corrected release follows:

Fewer Blood Components Transfused with fibryga® Than Cryoprecipitate, Secondary Analysis of Prespecified FIBRES Subgroups Reports

Findings published in the peer-reviewed Journal of Cardiothoracic and Vascular Anesthesia

Secondary findings do not change the primary outcomes of the FIBRES trial

PARAMUS, N.J. and TORONTO, Sept. 9, 2026 /PRNewswire/ -- A prespecified secondary analysis of the landmark FIBRES trial demonstrated that fibryga® (fibrinogen [human]) significantly reduced 24-hour allogeneic blood-product (ABP) transfusion requirements versus cryoprecipitate in two predefined, overlapping subgroups: patients in a non-critical state before surgery and patients undergoing elective surgery.1

These findings have been published as a peer-reviewed article in the Journal of Cardiothoracic and Vascular Anesthesia, titled Superiority of Fibrinogen Concentrate Versus Cryoprecipitate for Treatment of Bleeding in Cardiac Surgery Patients: A Secondary Analysis of the FIBRES Randomized Clinical Trial Stratified by Surgical Risk.

The newly published analysis evaluated two subgroups that had been defined before the trial results were analyzed. Results from this analysis do not change the primary conclusion of the primary FIBRES trial. In the overall study population, fibryga® met the trial's prespecified criterion for non-inferiority to cryoprecipitate.2,3

"These findings provide additional evidence and guidance around fibrinogen replacement in cardiac surgery patients who develop clinically significant bleeding and acquired hypofibrinogenemia," said Justyna Bartoszko, M.D., lead author of the analysis and a member of the FIBRES Research Group. "Blood transfusions can be lifesaving, but an efficient patient blood management strategy seeks to avoid unnecessary exposure to allogeneic blood components, as they are known to increase the risk of postoperative complications."4

Findings from the secondary subgroup analysis

The first subgroup consisted of participants from the FIBRES trial who were determined to be in a non-critical state before surgery (n=634), representing 86% of the primary analysis population. In this subgroup, there was a 16% relative reduction in ABP units transfused within 24 hours in patients receiving fibryga® versus cryoprecipitate (13.6 units vs. 16.2 units).

The second subgroup consisted of FIBRES trial participants undergoing elective surgery (n=466), representing 63% of the primary analysis population. In this subgroup, there was a 19% relative reduction in ABP units transfused within 24 hours in patients receiving fibryga® versus cryoprecipitate (11.7 units vs. 14.4 units).

"When clinically appropriate for a patient with acquired fibrinogen deficiency, a standardized fibrinogen concentrate provides targeted replacement," said Huub Kreuwel, Ph.D., Vice President of Medical Affairs, Octapharma USA.5 "While the primary results from FIBRES have not changed, secondary analyses such as these provide relevant information about specific patient subgroups which may be useful for informing institutional patient blood management protocols."

Safety findings

In the full study population, 248 (66.7%) patients in the fibryga® group and 264 (72.7%) patients in the cryoprecipitate group experienced treatment-emergent adverse events during the study (relative risk, 0.92; 95% CI, 0.83-1.01; P=0.07).

Within the elective-surgery subgroup, adverse events were less frequent among patients assigned to fibryga® than among patients assigned to cryoprecipitate (relative risk, 0.85; 95% CI, 0.75-0.97; P=0.02). Serious adverse events were also less frequent among fibryga® recipients in the elective surgery subgroup (relative risk, 0.71; 95% CI, 0.52-0.99; P=0.04).

No treatment-emergent AEs, SAEs, or deaths in the study were deemed to be possibly or probably related to FC or cryoprecipitate.

These findings should not be interpreted as establishing an overall safety advantage, and the safety of fibryga® should be evaluated in accordance with its current U.S. prescribing information.

About the FIBRES trial

The U.S. Food and Drug Administration's approval of fibryga® for fibrinogen replacement in patients with acquired fibrinogen deficiency (AFD) was supported by the landmark FIBRES study published in JAMA. The study demonstrated that fibrinogen concentrate is non-inferior to cryoprecipitate in managing bleeding following cardiac surgery, with the added benefits of standardized dosing, faster preparation, and reduced risk of viral transmission.

FIBRES was an investigator-initiated, pragmatic, multicenter, randomized clinical trial conducted at 11 Canadian hospitals (ClinicalTrials.gov Identifier NCT03037424). The study enrolled adults undergoing cardiac surgery who developed clinically significant bleeding and acquired hypofibrinogenemia after cardiopulmonary bypass for whom fibrinogen replacement was ordered. The FIBRES trial was supported by an unrestricted grant from Octapharma, which also provided the fibrinogen concentrate used in the study. Funding was also provided by the Canadian Institutes of Health Research. Cryoprecipitate was provided by Canadian Blood Services and Héma-Québec. Full author disclosures are reported in the published article.

A total of 827 patients were randomized. Of these, 735 patients received study treatment and were included in the primary analysis: 372 received fibryga® and 363 received cryoprecipitate. Each ordered dose consisted of 4 grams of fibryga® or 10 units of cryoprecipitate during the first 24 hours after cardiopulmonary bypass.

The primary endpoint was the cumulative number of allogeneic blood-component units – red blood cells, platelets and plasma – administered during the first 24 hours after bypass. In the overall population, the mean number of blood-component units administered was 16.3 with fibryga® and 17.0 with cryoprecipitate. The ratio of the means was 0.96, with a two-sided 95% confidence interval of 0.84 to 1.09. The trial met its prespecified non-inferiority criterion, with P0.001 for non-inferiority. The test for superiority in the overall population was not statistically significant, with P=0.50.

About fibryga®

fibryga® is a human fibrinogen concentrate indicated for: fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency; and treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

fibryga® is not indicated for dysfibrinogenemia.

Contraindications

Anaphylactic or severe reactions to fibryga® or its components (Sodium Citrate Dihydrate; Glycine; L-Arginine Hydrochloride).

Warnings and Precautions

Monitor patients for early signs of hypersensitivity or allergic reactions. If necessary, discontinue administration and institute appropriate treatment.

Thrombotic events have been reported in patients receiving fibryga®. Treatment with human fibrinogen concentrate in congenital fibrinogen deficiency has been associated with thrombosis at target plasma fibrinogen levels that were below 150 mg/dL. The thrombotic risks may be greater when the target fibrinogen plasma level is 150 mg/dL. Weigh the benefits of administration versus the risks of thrombosis.

fibryga® is made from pooled human plasma. Products made from human plasma may contain infectious agents, e.g., viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

Adverse Reactions

The most serious adverse reactions that may be observed with fibryga® are thromboembolic episodes and anaphylactic-type reactions. The most common adverse reactions observed in clinical studies with fibryga® in acquired fibrinogen deficiency (>5% of patients) were abnormal hepatic function, acute kidney injury, anemia, atrial fibrillation, delirium and renal failure.

The most common adverse reactions observed in clinical studies with fibryga® in congenital fibrinogen deficiency (>5% of patients) were nausea, vomiting, pyrexia (fever), and thrombocytosis.

For full prescribing information, please visit fibrygausa.com/pi. For more information on fibryga®, please visit fibrygausa.com.

About Octapharma 

Octapharma is one of the world's largest human protein manufacturers, developing and producing therapies from human plasma and human cell lines. Headquartered in Lachen, Switzerland, Octapharma has over 11,000 employees and serves patients in 117 countries across Immunotherapy, Hematology, and Critical Care.

With seven R&D sites, five manufacturing facilities in Europe, and more than 200 plasma donation centers in the U.S. and Europe, Octapharma has delivered trusted therapies for over 40 years. The company is committed to improving lives through innovation, quality, and a deep focus on patient care and clinical partnership. To learn more please visit www.octapharma.com.

References

- Bartoszko J, Karkouti K, Callum JL; FIBRES Research Group. Superiority of Fibrinogen Concentrate Versus Cryoprecipitate for Treatment of Bleeding in Cardiac Surgery Patients: A Secondary Analysis of the FIBRES Randomized Clinical Trial Stratified by Surgical Risk. J Cardiothorac Vasc Anesth. Published online June 17, 2026. doi:10.1053/j.jvca.2026.06.019.

- Callum JL, Farkouh ME, Scales DC, et al.; FIBRES Research Group. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA. 2019;322(20):1966-1976. doi:10.1001/jama.2019.17312.

- Fibryga® [Fibrinogen (Human)]. U.S. Prescribing Information. Octapharma USA, Inc. Revised August 2025.

- U.S.

National EHS leader strengthens regional investment to help manufacturers and other industrial employers build safer workplaces

MINNEAPOLIS, Sept. 11, 2026 /PRNewswire/ -- U.S. Compliance (USC), a national leader in environmental, health and safety (EHS) compliance services, announced today an expanded investment in the greater Chicago region through adding a deeper bench of local EHS professionals and increased support for Chicagoland manufacturers.

"The expansion reflects growing demand among area businesses for experienced safety and environmental compliance resources that help organizations navigate increasingly complex regulatory requirements," said Jim Ginther, chief executive officer of USC. "By expanding our local presence, we're making it easier for companies to access the expertise they need to protect their employees, maintain compliance, and improve business performance."

While USC has been serving the Chicagoland market for over 30 years, with hundreds of existing clients and a well-established team of professionals based in the market, the company is deepening its engagement with the region's manufacturing community, including sponsoring and speaking at the Chicagoland Safety, Health and Environmental Conference, Sept. 14–16, 2026.

The company also plans to expand its team of bilingual EHS advisors, including Spanish-speaking professionals, grow its team of environmental specialists, and enhance its digital capabilities to make training, compliance resources and EHS support more accessible to Chicagoland manufacturers.

"Chicago is one of the nation's most important industrial and manufacturing markets," said Chris Whitehorne, regional vice president of USC. "While many organizations recognize the importance of workplace safety, hiring and retaining experienced EHS professionals continues to be a challenge. USC can help bridge that gap by providing companies with a dedicated advisor supported by a broader team of specialists in OSHA compliance, environmental compliance, industrial hygiene, training, permitting and reporting."

Founded in 1988, U.S. Compliance is a leading provider of EHS solutions, serving more than 2,200 organizations across North America. The company pioneered the Compliance as a Service (CaaS) model, providing organizations with access to dedicated EHS professionals, specialized subject matter experts, training resources, digital compliance technology, and ongoing support through a predictable monthly subscription.

Media Contact: Chris Naylor

U.S. Compliance

612-802-9137

[email protected]

www.uscompliance.com

SOURCE U.S. Compliance

Share this article

BENTONVILLE, Ark., Sept. 11, 2026 /PRNewswire/ -- The Pinnacle Fertility Network is growing into Northwest Arkansas and is now scheduling patients for its upcoming Bentonville location. This new clinic location will expand access to fertility care, supported by a network built to serve every path to parenthood.

Care in Northwest Arkansas will be led by Shauna McKinney, MD, Medical Director of Pinnacle Fertility Oklahoma. Dr. McKinney will be joined by McKenzie Stock, NP, and an experienced clinical and laboratory team.

Patients can now book directly online.

Dr. McKinney is a fellowship-trained reproductive endocrinology and infertility specialist who has cared for patients across Oklahoma and the surrounding region for years. Her expertise includes IVF, ICSI and genetic testing. She also provides care for patients navigating infertility, endometriosis, fibroids, PCOS and recurrent pregnancy loss.

McKenzie brings direct fertility care experience and deep roots in Northwest Arkansas. She has been providing individualized fertility care to patients in the Bentonville and Rogers area for years and lives locally in the community she serves. Her work has included treatment planning, patient education, care coordination, and in-office procedures. Her background in women's health and practice development will help the Bentonville team deliver a responsive and personal patient experience from day one.

"We are thrilled to bring Pinnacle Fertility care to Northwest Arkansas," said Dr. McKinney. "Fertility care is deeply personal. Our goal is to ensure every patient feels heard, supported and confident in their care from their very first visit."

"I am thrilled to continue serving patients in the Northwest Arkansas community and to bring Pinnacle's full network of support closer to home," said Stock. "I know how important it is for patients to have a team that listens, communicates clearly and helps them feel supported through every step of their journey."

The upcoming Bentonville location reflects Pinnacle Fertility Network's commitment to recognizing where patients need greater access to fertility care and acting on that need. In addition to care from their local team, patients will benefit from the resources of the broader Pinnacle Fertility Network.

Those resources include integrated clinical data systems, shared physician innovation and collaboration, and advanced laboratory technologies. Patients also have coordinated access to Pinnacle Egg Bank, Pinnacle Surrogacy and Pinnacle's mental health program. Together, these resources help patients access the care and support that may be right for their family-building journey.

"When we see a need for expert fertility care in a community, we act," said Beth Zoneraich, Chief Executive Officer of Pinnacle Fertility. "We are proud to bring an experienced local team and the full strength of the Pinnacle Fertility Network to Northwest Arkansas. Patients deserve exceptional care and support no matter how they hope to build their family."

To schedule a consultation, visit pinnaclefertility.com/self-schedule. Learn more about McKenzie Stock, NP and Shauna McKinney, MD.

About Pinnacle Fertility, Inc.

Pinnacle Fertility, Inc. supports a premier network of physician-led fertility clinics committed to transforming dreams of parenthood into reality. Headquartered in Scottsdale, Arizona, Pinnacle manages a nationwide network of more than 50 clinic locations and 17 state-of-the-art embryology laboratories. With a team of more than 1,200 dedicated professionals, Pinnacle Fertility empowers clinics to help individuals and couples build the families of their dreams.

Media Contact

[email protected]

SOURCE Pinnacle Fertility

Share this article

Agency reflects on quarter-century, future of protecting nation's transportation systems

WASHINGTON, Sept. 11, 2026 /PRNewswire/ -- The Transportation Security Administration (TSA) today commemorated the 25th anniversary of the September 11, 2001, terrorist attacks, honoring the nearly 3,000 lives lost and reaffirming the agency's commitment to protecting the nation's transportation systems and staying ahead of evolving threats.

In response to the 9/11 attacks, TSA was created when President George W. Bush signed the Aviation and Transportation Security Act into law on November 19, 2001, to strengthen transportation security and restore confidence in the aviation system. The agency's mission remains unchanged: to protect the nation's transportation systems to ensure freedom of movement for people and commerce.

"For 25 years, the men and women of TSA have carried out this mission with vigilance, professionalism and an unwavering commitment to the American people," TSA Administrator David P. Cummins said. "As we remember those we lost on September 11 and honor the service that followed, we also look ahead. The threats we face today are sophisticated and constantly evolving. TSA must modernize to defend against those threats. Under President Trump and Secretary Mullin, we've launched the Horizon 25 Strategy to advance our capabilities across all modes of transportation to ensure 9/11 never happens again. Not on our watch."

Over the past 25 years, TSA has evolved from a newly formed federal screening workforce into a sophisticated, intelligence-driven, risk-based security agency. Today, aviation security begins well before a passenger reaches the checkpoint and includes intelligence analysis and information sharing, passenger vetting, advanced screening technology, canine teams, Federal Air Marshals, inspectors and close coordination with airports, airlines, law enforcement and international partners.

Technology has transformed the checkpoint through TSA's deployment of computed tomography, advanced imaging technology, credential authentication technology and facial comparison technology. TSA PreCheck® and other risk-based security initiatives help the agency focus resources where they provide the greatest security value while improving the passenger experience.

Beyond our airports, TSA is responsible for securing other modes of transportation, including ports, railways, and pipelines, as well as major events like America's 250th anniversary celebrations and the FIFA World Cup 2026™.

TSA's approximately 60,000 employees remain at the center of the agency's mission. Transportation security officers and other TSA professionals operate increasingly sophisticated technologies, help identify and respond to potential threats, and adapt as the threat environment changes.

Looking ahead, TSA will continue upgrading screening technology, strengthening identity management, expanding risk-based security and improving the passenger experience. The agency will also continue adapting to emerging threats, including cyber risks and unmanned aircraft systems, while strengthening partnerships across government and industry.

Twenty-five years after September 11, TSA's mission endures: to stay ahead of evolving threats, keep transportation moving, and protect the freedom of movement for people and commerce that is fundamental to the American way of life. In honor of that legacy, TSA has launched a 25th anniversary commemorative website. We invite the public to visit TSA.gov for more information on our enduring mission.

SOURCE Transportation Security Administration

Share this article

– Revenue increased 53% to $30.8 million – Operating income increased 59% to $7.4 million

– Net income increased 43% to $5.3 million – Earnings per share increased to $0.08 from $0.06

NEW CENTURY, Kan., Sept. 11, 2026 /PRNewswire/ -- Butler National Corporation (OTCQX: BUKS), a leader in the growing global market for aircraft modification, maintenance, repair and overhaul (MRO) and a recognized provider of gaming management services, announces its financial results for the first quarter of fiscal 2027. The Company will host a conference call on Friday, September 11, 2026 at 10:00 AM Central Time to review these results.

Management Comments

Adam Sefchick, Interim Chief Executive Officer of Butler National Corporation, commented on the results stating, "Butler National delivered record first-quarter earnings in fiscal 2027. These results reflect the dedication of our employees, the continued execution of our strategic initiatives, and our focus on operational efficiency across the organization. Revenue increased 53% to $30.8 million, operating income increased 59% to $7.4 million, and net income increased 43% to $5.3 million compared to the first quarter of fiscal 2026.

Importantly, our significant revenue growth translated into continued strong profitability, with operating margin increasing to 24% compared to 23% in the prior-year quarter. Earnings per share increased to $0.08 from $0.06, reflecting improved operating performance during the quarter. We also continued our disciplined approach to capital allocation, including ongoing share repurchases and investments in our businesses.

Within our Aerospace Products segment, strong performance from both Avcon Aircraft Modifications and Butler National-Tempe contributed significantly to our results, while Aerospace Products backlog reached a record $51.1 million. At Avcon, we achieved several significant milestones, including the successful completion and delivery of two Challenger 605/650 modification projects that included our recently approved STC for the under-fuselage radome/pod and rails for mounting of sensors. In addition, Avcon completed a complex special mission systems integration project, delivering a CASA CN-235 aircraft upgraded with a new sensor package that included a new Avcon-designed custom workstation. The project demonstrates Avcon's expanding capabilities beyond structural aircraft modification to provide more comprehensive special mission systems integration solutions, while creating opportunities for derivative products and potential follow-on installations. Special Mission Electronics (Tempe) continued to experience strong customer demand and increasing production volumes.

The increased sales of Avcon aircraft modification kits for customer installation also contributed to revenue and margin performance during the quarter. These included Cessna Caravan camera port modification kits, as well as Avcon rails and Special Mission Pod kits for the King Air. Kit sales remain an important part of our strategy to leverage Avcon's engineering and certification capabilities while expanding our geographic reach.

These results reflect the continued execution of strategic initiatives implemented over the last several years, including investments in new product development, manufacturing capabilities, and operational efficiency. We remain focused on customer satisfaction, operational excellence, and disciplined growth."

Jeffrey Yowell, Executive Chairman, commented: "Butler National's strong first-quarter results demonstrate the continued momentum across our businesses and the effectiveness of the strategy we have been executing. On behalf of the Board of Directors, I want to thank our employees for their continued dedication to serving our customers and executing at a high level every day.

As Butler National enters its next chapter of leadership and growth, the Board and management team remain focused on maintaining stability and continuing to execute the Company's strategic and operational priorities. While the Board conducts its search for a permanent Chief Executive Officer, we remain confident in Adam and our experienced leadership team and their ability to continue advancing the business.

Our objective remains to build upon the momentum already established across Butler National by investing in our capabilities, improving operational execution and pursuing disciplined opportunities for long-term growth and shareholder value creation."

Stockholders' equity increased 5% during the first quarter of fiscal 2027 while long-term liabilities declined 3%. During the first quarter of fiscal 2027, we repurchased 246,996 shares of our outstanding common stock for cash under our share repurchase program and as part of our ongoing capital allocation strategy.

Business Segment Highlights

Aerospace Products:

Revenue from the Aerospace Products segment increased 92% to $21.7 million in the first quarter of fiscal 2027 compared to $11.3 million in the first quarter of fiscal 2026. The increase in revenue was primarily driven by a $10.7 million increase in aircraft modification activity and a $0.7 million increase in the sales of Special Mission Electronics, partially offset by a $0.9 million decrease in Aircraft Avionics. Aircraft Modifications experienced higher activity across multiple programs, including increased work on larger and more complex special mission aircraft projects, as well as repeat modifications utilizing previously developed STCs.

Revenue also benefited from increased sales of modification kits for field installation, including Cessna Caravan camera port modification kits and Avcon rails and Special Mission Pod kits for the King Air, among others. Additionally, Avcon completed and delivered two Special Mission Challenger 605/650 modification projects that included our recently approved STC for the under-fuselage radome/pod and rails for mounting of sensors.

Aerospace Products operating income increased 91% compared to the prior-year quarter, while the segment maintained an operating margin of approximately 25% despite the significant increase in revenue and activity.

Butler National-Tempe continued to experience strong demand for its specialized electronic control systems and defense-related products, including deliveries of M134 minigun gun control units. Special Mission Electronics revenue increased $0.7 million during the quarter, supported by increased production activity, additional customer orders and production efficiencies.

Professional Services:

Revenue from the Professional Services segment increased 3% to $9.0 million in the first quarter of fiscal 2027 compared to $8.8 million in the first quarter of fiscal 2026.

Traditional casino gaming revenue increased $0.4 million due to increased patron spending. This increase was partially offset by a decrease in sports wagering revenue through the DraftKings sports wagering platform, which decreased to $1.1 million for the three months ended July 31, 2026, compared to $1.3 million for the three months ended July 31, 2025. Non-gaming revenue at Boot Hill Casino increased slightly to $1.1 million for the three months ended July 31, 2026, compared to $1.0 million for the three months ended July 31, 2025. The Company continues to pursue initiatives designed to increase visitation and enhance the entertainment offerings at Boot Hill Casino & Resort, including the development of the adjacent Glo Hotel property by a local hospitality provider.

Backlog:

As of July 31, 2026, Aerospace Products backlog totaled a record $51.1 million. Backlog represents contracted business that meets the Company's criteria for inclusion and includes orders that may not be completed within the next fiscal year. The timing of revenue recognition can vary based on customer schedules, aircraft availability, engineering and regulatory requirements, material availability and other factors.

Conference Call:

Participants to the conference call should call in at least 5 minutes prior to the start time. An audio recording of the conference call will be made available on the Butler National Corporation website Investor Page (https://butlernational.com/investing/) following the call until October 11, 2026. Shareholders are encouraged to submit questions in advance through the Company's investor relations website.

Our Business:

Butler National Corporation operates in the Aerospace and Professional Services business segments. The Aerospace Products segment includes the design, manufacture, sale and service of structural modifications, design, integration and installation of electronic equipment, systems and technologies that enhance aircraft operations, and the design, manufacture and sale of defense related articles. Additionally, we operate FAA Repair Stations. Companies in Aerospace Products concentrate on products and services for Learjet, Challenger, Textron Beechcraft King Air, and Cessna turboprop aircraft. Butler National-Tempe designs and manufactures robust electronic controls and cabling. The Professional Services segment includes the management of a gaming, dining and entertainment facility in Dodge City, Kansas. Boot Hill Casino and Resort features approximately 500 slot machines, 15 table games and a DraftKings branded sportsbook.

Forward-Looking Information:

Statements made in this press release, reports and proxy statements filed with the Securities and Exchange Commission (the "SEC"), communications to stockholders, and oral statements made by representatives of the Company that are not historical in nature, or that state the Company's or management's intentions, plans, beliefs, expectations or predictions of the future, may constitute "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended (the "Exchange Act").

DELRAY BEACH, Fla., Sept. 11, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Cryovials Market is projected to reach USD 0.31 billion by 2031 from USD 0.24 billion in 2026, at a CAGR of 5.5% during the forecast period.

Browse 200 market data Tables and 50 Figures spread through 250 Pages and in-depth TOC on "Cryovials Market - Global Forecast to 2031"

Cryovials Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 0.24 billion

- 2031 Projected Market Size: USD 0.31 billion

- CAGR (2026–2031): 5.5%

Cryovials Market Trends & Insights:

- By material, the glass is expected to register the highest CAGR of 7.0% during the forecast period.

- By application, the cell and gene therapy are expected to register the highest CAGR of 8.0%.

- By end user, the academic & research institutes are expected to register the highest CAGR of 6.5%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=31904528

The healthcare sector's increasing dependence on ultra-low-temperature storage for the long-term preservation of biological samples is a key factor driving the growth of the cryovials market. Rising adoption of hospital-based biobanking, expanding clinical and molecular diagnostic testing, and increasing genomic research are generating greater demand for reliable, contamination-resistant cryovials. Furthermore, the growing focus on personalized medicine, regenerative medicine, and cell and gene therapies is expanding the use of cryovials across hospitals, clinical laboratories, and research facilities.

At the same time, advancements in cell and gene therapy manufacturing and the increasing collection and storage of patient-derived biological specimens are creating new opportunities for specialized cryovial solutions. Healthcare institutions are increasingly seeking cryovials that offer improved temperature resistance, sterility, sample identification, and compatibility with automated storage systems. In addition, stronger regulatory emphasis on cold-chain management, sample traceability, and quality assurance from agencies such as the FDA and EMA is encouraging healthcare providers and laboratories to adopt validated, certified cryovials, supporting sustained market growth.

The glass segment holds the major share in the cryovials market in 2025.

Based on material, the cryovials market is segmented into plastic (polypropylene, polyethylene, and polystyrene) and glass vials. The plastic segment held the largest share of the cryovials market in 2025. Glass cryovials accounted for a significant share of the cryovials market in 2025, primarily due to their growing use for the long-term preservation of sensitive biological samples in biopharmaceutical research, vaccine development, cell biology, and biobanking. Their excellent chemical resistance, thermal stability, transparency, and low interaction with stored samples make glass cryovials well suited for applications requiring high levels of sample integrity. The continued expansion of biobanking and advanced therapeutic research is further supporting demand for dependable glass-based cryogenic storage solutions.

A key trend driving the adoption of glass cryovials is the growing focus on sample integrity and contamination-free, long-term storage. Research institutions and biopharmaceutical companies increasingly use high-quality cryovials to store valuable cells, tissues, and other biological materials at ultra-low temperatures. In addition, the growing adoption of regenerative medicine, genomics, and cell-based research is creating demand for cryovials with improved sealing performance, durability, and compatibility with automated storage systems, supporting the continued relevance of glass cryovials in specialized research and clinical applications.

The cell and gene therapy segment accounted for a significant share of the cryovials market, by application, in 2025.

Based on application, the cryovials market is segmented into cryopreservation and biobanking, clinical and diagnostic sample storage, drug discovery and development, cell and gene therapy, and transport of biological samples. The cell and gene therapy segment is experiencing strong growth in the cryovials market, supported by the increasing development and commercialization of advanced therapies, including CAR-T cell therapies, stem cell treatments, gene-modified therapies, and regenerative medicine. These applications require secure, consistent cryogenic storage across sample collection, processing, manufacturing, transportation, and administration to preserve cell viability and therapeutic performance. This growing need for reliable cold-chain storage is driving demand for sterile, high-quality cryovials designed for cell and gene therapy workflows.

Another important growth trend is the rising demand for validated, traceable, and high-performance cryovials that meet the stringent requirements of advanced therapy manufacturing. As cell and gene therapies move from early-stage clinical research to commercial-scale production, manufacturers are placing greater emphasis on sample integrity, contamination control, temperature resistance, and secure closure systems. The integration of barcode-based identification and compatibility with automated cryogenic storage systems is further accelerating the adoption of advanced cryovial solutions in this rapidly expanding segment.

The academic & research institutes are expected to register the highest CAGR

By end user, the cryovials market is segmented into hospitals and diagnostic laboratories, biobanks, pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs), and other end users. The academic and research segment is growing steadily in the cryovials market, supported by rising investments in life sciences, molecular biology, genomics, proteomics, cancer research, and personalized medicine. Universities, research institutions, and government laboratories are increasingly conducting studies that require long-term preservation of biological materials such as cells, tissues, DNA, RNA, and blood samples. This expanding research activity is driving demand for reliable cryogenic storage solutions that maintain sample quality and integrity over extended periods.

A major trend supporting growth in this segment is the increasing adoption of advanced, traceable, and automation-compatible cryovials. Research laboratories and academic biobanks are handling growing volumes of biological samples, driving greater demand for cryovials with 2D barcodes, secure closures, and formats compatible with automated storage systems. The growing emphasis on sample identification, inventory management, contamination control, and reproducibility in collaborative research is further encouraging laboratories to adopt high-performance cryovial solutions.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=31904528

The Asia Pacific market is projected to register the fastest growth in the market during the forecast period.

The Asia Pacific cryovials market is projected to grow the fastest from 2026 to 2031, driven by rapid advances in healthcare infrastructure, biotechnology, and academic research. Major industry players are expanding their manufacturing and cold-chain distribution capabilities across countries such as China, India, Japan, and South Korea to meet rising regional demand. Increasing government funding for biomedical research, rising healthcare expenditures, and the establishment of hospital-affiliated biobanking and cell therapy centers are further fueling market expansion. Additionally, the growing adoption of validated, certified cryovials in clinical diagnostic laboratories, coupled with a shift toward precision medicine and automation, is creating significant growth opportunities for global and regional players operating in the APAC cryovials market.

Key Players

Leading players in the Cryovials companies include Thermo Fisher Scientific Inc. (US), Corning Incorporated (US), Merck KGaA (Germany), DWK Life Sciences GmbH (Germany), Avantor, Inc. (US), Eppendorf SE (Germany), SARSTEDT AG & Co. KG (Germany), Sumitomo Bakelite Co., Ltd. (Japan), Biologix Group Limited (China), and Brooks Automation, Inc. (US), among others.

Cryovials Market - Investment & funding +Merger & Acquisition

Investment Funding Context

The cryovials market is supported by investment across the broader healthcare, life-sciences, biopharmaceutical, and laboratory-storage ecosystem rather than by funding focused exclusively on cryovials. Capital deployment in biopharmaceutical R&D, cell and gene therapy, clinical research, biobanking, regenerative medicine, diagnostics, and pharmaceutical manufacturing is driving demand for reliable cryogenic sample-storage solutions. Increasing investments in healthcare infrastructure, research laboratories, biological sample repositories, and advanced cold-chain systems are contributing to the expansion and modernization of cryovial storage capabilities worldwide.

Revenue Shift Context

The cryovials market is gradually shifting revenue from basic, manually handled storage products toward higher-value cryovial systems that offer improved sample protection, traceability, durability, and compatibility with automated laboratory workflows. Conventional cryovials continue to account for a significant share of unit sales because of their widespread use in hospitals, diagnostic laboratories, academic research centers, biobanks, pharmaceutical companies, and biotechnology facilities. However, revenue growth is increasingly concentrated in sterile, high-performance, barcoded, automation-compatible, and application-specific cryovials designed for biobanking, cell and gene therapy, vaccine development, and long-term preservation of biological specimens.

DELRAY BEACH, Fla., Sept. 11, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Sepsis Diagnostics Market is projected to reach USD 1.22 billion by 2031 from USD 0.83 billion in 2026, at a CAGR of 7.9% during the forecast period.

Browse 400 market data Tables and 310 Figures spread through 500 Pages and in-depth TOC on "Sepsis Diagnostics Market- Global Forecast to 2031"

Sepsis Diagnostics Market Size & Forecast:

- Market Size Available for Years: 2026–2031

- 2026 Market Size: USD 0.83 billion

- 2031 Projected Market Size: USD 1.22 billion

- CAGR (2026–2031): 7.9%

Sepsis Diagnostics Market Trends & Insights:

- North America accounted for the largest market share, by region, in 2025: 43.2%.

- By product, in 2025, the assays & kits & reagents segment had the largest share of 40.7%.

- Hospital & specialty clinics dominated the sepsis diagnostics market in 2025, with a share of 62.7%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=92673155

Growth is driven by the high incidence of sepsis and bloodstream infections (BSIs), increasing adoption of rapid molecular and syndromic diagnostics, a growing focus on antimicrobial stewardship (AMS), the expansion of biomarker-based testing, and rising demand for faster pathogen identification and treatment decision support.

Assays & reagent kits accounted for the largest share of the global sepsis diagnostics market, by product, in 2025.

By product, the sepsis diagnostics market is segmented into blood culture media, assays & reagent kits, instruments, and software. In 2025, assays & reagent kits accounted for the largest share, driven by their recurring use across blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. Growing demand for pathogen detection kits, sepsis biomarker assays, PCR-based reagents, and syndromic testing panels continues to support this segment's dominance. Instruments also held a significant share, driven by the increasing installation of automated blood culture systems, molecular diagnostic platforms, mass spectrometry systems, and clinical chemistry analyzers in hospitals and reference laboratories.

Blood culture/microbiology testing accounted for the largest share of the sepsis diagnostics market, by technology, in 2025.

By technology, the market is segmented into blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry and blood gas analysis. In 2025, blood culture/microbiology testing accounted for the largest share, reflecting its established role as the standard approach for detecting bloodstream infections and supporting antimicrobial susceptibility testing. Molecular diagnostics is expected to grow strongly over the forecast period, supported by increasing adoption of PCR/RT-PCR, multiplex PCR panels, microarrays, FISH/PNA-FISH, DNA sequencing, NGS, LAMP, and TMA-based methods for faster pathogen identification and resistance marker detection.

Bacterial sepsis accounted for the largest share of the sepsis diagnostics market, by pathogen type, in 2025.

By pathogen type, the market is segmented into bacterial sepsis, fungal sepsis, and other pathogen types, including parasitic and polymicrobial sepsis. In 2025, bacterial sepsis accounted for the largest share, supported by the high burden of bacterial bloodstream, hospital-acquired, and ICU-related infections, as well as the strong clinical need for pathogen identification and antimicrobial susceptibility testing. Gram-negative and Gram-positive bacterial sepsis remain key subsegments due to their significant role in severe infections and antimicrobial resistance concerns. Fungal sepsis is expected to attract attention as cases rise among immunocompromised patients, oncology patients, transplant recipients, and critically ill ICU patients.

Laboratory tests accounted for the largest share of the sepsis diagnostics market, by test type, in 2025.

By test type, the sepsis diagnostics market is segmented into laboratory and point-of-care tests. In 2025, laboratory tests accounted for the largest share, driven by the central role of hospital laboratories, microbiology departments, and reference laboratories in blood culture testing, molecular diagnostics, immunoassays, antimicrobial susceptibility testing, mass spectrometry, and clinical chemistry testing. Point-of-care tests are expected to grow rapidly due to rising demand for rapid sepsis screening, emergency department testing, ICU-based decision support, and decentralized biomarker-based assessment.

Whole blood accounted for the largest share of the sepsis diagnostics market, by sample type, in 2025.

By sample type, the sepsis diagnostics market is segmented into whole blood and serum. In 2025, whole blood accounted for the largest share, supported by its established use in blood culture testing, molecular pathogen detection, bloodstream infection diagnosis, and sepsis-related microbiology workflows. Whole blood remains central to sepsis diagnosis because detecting bloodstream infections and identifying pathogens require direct or culture-based analysis of blood samples. Serum-based testing also holds an important share due to its use in immunoassays, inflammatory biomarker testing, host-response assessment, and clinical chemistry-based evaluation of sepsis severity.

Hospitals & specialty clinics accounted for the largest share of the sepsis diagnostics market, by end user, in 2025.

By end user, the market is segmented into hospitals and specialty clinics, pathology and reference laboratories, and research laboratories, academic institutes, and CROs. In 2025, hospitals and specialty clinics accounted for the largest share, driven by the high sepsis burden in emergency departments, ICUs, inpatient wards, and critical care settings. Hospitals are the primary users of blood culture systems, rapid molecular tests, clinical chemistry analyzers, blood gas analyzers, and antimicrobial stewardship-linked diagnostic workflows. Pathology and reference laboratories also play an important role by supporting high-volume infectious disease testing, confirmatory diagnostics, molecular testing, and outsourced microbiology services.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=92673155

North America accounted for the largest regional share of the global sepsis diagnostics market in 2025.

The sepsis diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, North America accounted for the largest share, driven by advanced hospital infrastructure, high adoption of automated blood culture systems and molecular diagnostics, strong antimicrobial stewardship initiatives, favorable adoption of rapid diagnostics, and the presence of leading diagnostic companies. Europe remains a significant market due to established microbiology laboratory networks, robust infectious disease testing infrastructure, and an increasing focus on sepsis management and antimicrobial resistance control. Asia Pacific is expected to grow fastest, driven by rising healthcare expenditure, expanding hospital infrastructure, a growing burden of infectious diseases and bloodstream infections, and increasing adoption of automated and molecular diagnostic platforms.

Key Players

Leading players in the Sepsis Diagnostics companies include F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Hologic, Inc. (US), Agilent Technologies, Inc. (US), Becton, Dickinson and Company (US), Koninklijke Philips N.V. (Netherlands), Merck KGaA (Germany), Bio SB (US), and Sakura Finetek Japan Co., Ltd. (Japan).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155

Sepsis Diagnostics Market - Investment & funding +Merger & Acquisition

Investment Funding Context

Investment activity in sepsis diagnostics is enabling earlier recognition of sepsis, faster pathogen identification, and rapid antimicrobial susceptibility testing (AST). Recent financing reflects strong backing for diagnostic developers approaching or expanding commercialization. Cytovale raised USD 84 million in Series C financing in November 2023, led by Norwest Venture Partners, followed by USD 100 million in Series D financing in October 2024, led by Sands Capital, to expand adoption of IntelliSep in US hospitals. The Series C included the conversion of bridge notes. Inflammatix secured USD 57 million in Series E financing in September 2024, led by Khosla Ventures and Think.Health, to support regulatory work and early commercialization of its TriVerity acute infection and sepsis test.

Capital is also supporting treatment guidance and testing closer to patients. Selux Diagnostics announced in April 2024 that RA Capital Management led a USD 48 million funding round for US commercialization of its rapid AST platform, including testing of positive blood cultures. In October 2024, Ad Astra Diagnostics announced a USD 5 million BARDA contract, with potential total funding of up to USD 12.6 million, to develop a blood-count and severe-infection detection system. The latter amount is a potential contract ceiling; the award and Selux financing cover applications beyond sepsis alone.

Established suppliers also invest through internal development: bioMérieux reported EUR 507.4 million (USD 572.6 million) in group R&D expenses in 2025, though this is not a sepsis-specific investment figure. Commercial adoption remains a material constraint. Its EUR 141 million (USD 159.14 million) impairment of VITEK REVEAL technology in 2025 reflected slower market development and a more gradual commercial ramp-up. Analyst assessment: funding prospects depend on clinical utility, hospital implementation, sustained test utilization, and technical performance.

PLYMOUTH, Mich., Sept. 11, 2026 /PRNewswire/ -- Esperovax, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 18/038,673, entitled "Yeast-Based Expression of Therapeutic Proteins In Vivo."

The allowed patent application covers technology developed by Esperovax for using engineered yeast as a platform for the in vivo production of therapeutic proteins. The approach is designed to enable therapeutic proteins to be produced directly within the body following administration of engineered yeast, creating opportunities for localized, sustained, and potentially more accessible delivery of biologic medicines.

The allowance represents an important expansion of Esperovax's intellectual property portfolio and provides protection for a technology platform with potential applications across multiple therapeutic areas.

"This patent allowance validates an important part of the scientific foundation we have built at Esperovax," said David O'Hagan, Ph.D., CEO of Esperovax. "Rather than manufacturing every therapeutic protein externally and repeatedly administering the purified biologic, our technology creates the possibility of programming yeast to function as an in vivo therapeutic protein production system. We believe this approach could ultimately enable new ways of delivering biologic medicines."

The technology is particularly compelling for applications in which localized or sustained expression of therapeutic proteins could provide advantages over conventional systemic protein administration.

Following completion of the USPTO's issuance requirements, the application is expected to proceed to issuance as a U.S. patent.

About Esperovax

Esperovax, Inc. is a biotechnology company developing innovative nucleic-acid and biologic technologies designed to enable new approaches to the prevention and treatment of disease. The company's intellectual property portfolio includes platforms for engineered biological delivery and therapeutic protein expression.

U.S. Patent Application No. 18/038,673 — "Yeast-Based Expression of Therapeutic Proteins In Vivo."

SOURCE Esperovax

Share this article

Government inspection records and nearly 2,000 accounts from multiple states expose recurring pricing failures and lost customer trust

CINCINNATI, Sept. 11, 2026 /PRNewswire/ -- Government inspectors found overcharging at more than one in three Kroger stores examined across nine Ohio jurisdictions (36 of 101), according to a report released this week by the Center for Responsible Food Business (CRFB). Pricing errors favored Kroger nearly three times as often as they favored shoppers.

The report, Kroger's Pricing Problem, pairs those inspection findings with nearly 2,000 accounts submitted through CRFB's Kroger Hurts Families campaign. Customers, employees, and suppliers describe pricing problems ranging from repeated overcharges to misleading sales and difficulty accessing advertised discounts.

The government records, obtained through public-records requests, cover 389 inspections from 2022 to mid-2026. Inspectors recorded 644 incorrect prices, and overcharges averaged more than 20 percent above shelf prices.

"People go to Kroger to feed their families, not to get ripped off at the register. Customers are telling us they have to photograph price tags, challenge their receipts, and fight for refunds," said Taylor Warren, president of CRFB. "When people need that kind of protection from their own grocery store, the company has failed them."

Key findings

- Repeated inspection failures: 58 of 389 inspections failed in the Ohio records. More than one in three stores examined was caught overcharging at least once.

- Recurring overcharges: 557 relevant submissions (29 percent) described overcharging. Shoppers also reported confusion over Kroger's price guarantees and repeated trips to customer service to recover their money.

- Misleading sales: 247 submissions (13 percent) described misleading signage, including fine-print purchase conditions and "sales" that shoppers said offered no real discount.

- Inaccessible discounts: 139 submissions (7 percent) described difficulty obtaining digital-only prices, including accounts concerning seniors, disabled shoppers, and people without smartphones.

- High prices and limited alternatives: 40 percent of relevant submissions described high, rising, or unaffordable prices; 8 percent alleged higher prices where shoppers lacked alternatives.

A year ago, Consumer Reports found Kroger was overcharging customers by an average of 18 percent across 26 stores; our new report shows the mega-retailer has not corrected the issue.

"I have been overcharged too many times to count, to the point where I just accept it," one shopper wrote.

"When an overcharge goes unnoticed, Kroger keeps money the customer was never supposed to pay," Warren said. "Those extra dollars matter to working families trying to afford food. Calling it a pricing error does not make it harmless."

About Kroger Hurts Families

CRFB has run more than $3 million in television advertisements across its Kroger Hurts Families campaign. Launched in May 2026, the campaign has used these ads to invite shoppers and employees to share their experiences at KrogerHurtsFamilies.com.

This report focuses on pricing; the broader campaign also addresses food quality, safety, labor issues, and consumer privacy concerns.

CRFB is calling on Kroger to honor its price tags, make discounts accessible, provide clear remedies for overcharges, and stop charging more in communities with few alternatives.

Read the report: Kroger's Pricing Problem

About CRFB: The Center for Responsible Food Business is a national nonprofit that holds food companies accountable to their customers.

Media contact: James Grant | [email protected]

SOURCE Center for Responsible Food Business

Share this article